Department of Pharmaceutical Technology and Chemistry, Faculty of Pharmacy and Nutrition, Universidad de Navarra, C/Irunlarrea 1, 31008 Pamplona, Spain.
Department of Pharmaceutical Technology and Chemistry, Faculty of Pharmacy and Nutrition, Universidad de Navarra, C/Irunlarrea 1, 31008 Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra, IdiSNA, C/Irunlarrea 3, 31008 Pamplona, Spain.
Int J Pharm. 2020 May 15;581:119283. doi: 10.1016/j.ijpharm.2020.119283. Epub 2020 Mar 30.
Even though substantial advances in understanding glioma pathogenesis have prompted a more rational design of potential therapeutic strategies, glioblastoma multiforme remains an incurable disease with the lowest median overall survival among all malignant brain tumours. Therefore, there is a dire need to find novel drug delivery strategies to improve the current dismal survival outcomes. In this context, nanomedicine offers an appealing alternative as it shows potential to improve brain drug delivery. Accordingly, we here review nanomedicine-based drug delivery strategies tested in orthotopic animal models of glioblastoma intended to improve the efficacy of the drug candidates that are currently used in the clinical setting or that have entered clinical trials for the treatment of glioblastoma multiforme. We also outline the future perspectives of nanotechnology to provide emerging glioblastoma treatment with broad translational clinical potential based on the nanocarriers that have already entered the clinical trials stage for the treatment of malignant glioma.
尽管在理解神经胶质瘤发病机制方面取得了重大进展，促使人们更合理地设计潜在的治疗策略，但多形性胶质母细胞瘤仍然是一种无法治愈的疾病，其总体中位生存期在所有恶性脑肿瘤中最低。因此，迫切需要寻找新的药物输送策略，以改善目前惨淡的生存结果。在这种情况下，纳米医学提供了一种有吸引力的选择，因为它显示出改善脑部药物输送的潜力。因此，我们在这里回顾了在神经胶质瘤的原位动物模型中测试的基于纳米医学的药物输送策略，旨在提高目前用于临床或已进入临床试验用于治疗多形性胶质母细胞瘤的候选药物的疗效。我们还概述了纳米技术的未来前景，为新兴的神经胶质瘤治疗提供广泛的转化临床潜力，基于已经进入临床试验阶段用于治疗恶性神经胶质瘤的纳米载体。
